Kamada (KMDA)
NASDAQ:KMDA
KMDA Stock Chart & Stats
$8.44
$0.85(12.50%)
At close: 4:00 PM EST
$8.44
$0.85(12.50%)
Day’s Range― - ―
52-Week Range$6.15 - $9.35
Previous CloseN/A
Volume680.22K
Average Volume (3M)69.04K
Market Cap
$490.98M
Enterprise Value$422.95M
Total Cash (Recent Filing)$75.48M
Total Debt (Recent Filing)$11.56M
Price to Earnings (P/E)18.7
Beta0.64
Next Earnings
May 26, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding57,686,054
10 Day Avg. Volume36,209
30 Day Avg. Volume69,036
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.52
Price to Sales (P/S)2.09
P/FCF Ratio24.14
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit5.51
Enterprise Value/Ebitda11.14
Forecast
1Y Price Target
$13.00Price Target Upside54.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$648.35K
Bulls Say, Bears Say
Bulls Say
Commercial Portfolio ExpansionAnalyst notes that broader U.S. and international penetration of the commercial portfolio, supported by increased U.S. sales of VARIZIG and KEDRAB and ex-U.S. strength in KAMRAB and GLASSIA, should drive revenue growth.
Distribution And Biosimilar LaunchesAnalyst highlights that expansion of the Distribution segment and planned biosimilar launches provides a scalable, diversified revenue source beyond existing specialty products.
Plasma Collection And Vertical IntegrationAnalyst views the ramp of in-house plasma collection operations, including regulatory approval for the San Antonio site, as an underappreciated contributor to future revenue and margin improvement through lower specialty plasma input costs.
Bears Say
Capital Reallocation UncertaintyAnalyst raises uncertainty about how capital freed from the discontinued trial will be reallocated, which could delay investments needed to accelerate growth across the existing portfolio.
Clinical Trial DiscontinuationAnalyst notes that discontinuation of a key Phase 3 inhaled therapy trial creates uncertainty about the drug development pipeline and removes a potential future revenue catalyst.
Reduced Royalty RateAnalyst warns that a reduced GLASSIA royalty rate from a partner will lower product royalty income and could pressure revenue.
Kamada News
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was $6.15 and its highest was $9.35 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is $490.98M.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is May 26, 2026 which is in 42 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Mar 11, 2026. The company reported $0.068 earnings per share for the quarter, missing the consensus estimate of $0.078 by -$0.01.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Notavailable dividend of $0.2 which represents an annual dividend yield of N/A. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 0.12.
How many shares outstanding does Kamada have?
Kamada has 57,686,054 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of $0.068 in its last earnings report, missing expectations of $0.078. Following the earnings report the stock price went down -4.577%.
Which hedge fund is a major shareholder of Kamada?
Currently, no hedge funds are holding shares in KMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (54.03% Upside)
$13.00 (54.03% Upside)
Blogger Sentiment
Bullish
KMDA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 256.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.01%
12-Months-Change
Fundamentals
Return on Equity
7.75%
Trailing 12-Months
Asset Growth
1.73%
Trailing 12-Months
Company Description
Kamada
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
KMDA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: Kamada reported double-digit revenue growth (+12%), strong adjusted EBITDA expansion (+23%), a 40% increase in net income, solid operating cash generation, a declared dividend, and constructive 2026 organic guidance (+13% revenue midpoint). Commercial strengths include strong KEDRAB performance with multi-year commitments, GLASSIA contribution, VARIZIG growth and secured Canadian tender, plus planned biosimilar launches and plasma collection expansion that provide multi-year upside. Offsetting items include a decline in CYTOGAM revenues due to increased antiviral use, a modest gross margin decline (42% vs 43%), a small reduction in cash balance after dividend and financing uses, higher G&A, Q4 sequential margin pressure, and a multi-year timeline to realize specialty plasma margin benefits. Overall, the positive operational and financial momentum and confident organic guidance materially outweigh the headwinds.View all KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
$13.00
▲(54.03% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.52% Mutual Funds
4.15% Other Institutional Investors
93.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---